Novel lipid and ascorbyl stearate biomimetic vancomycin-loaded nanostructured lipid carrier therapy for bacterial infections and sepsis

This is the authors' abstract. We don't add key points for this paper.

antioxidant and anti-inflammatory assays confirmed significant ROS scavenging capacity and suppression of LPS-induced IL-1β and TNF-α in RAW264.7 cells. In the mice sepsis model, NLC-VCM treatment significantly reduced bacterial load (73.9% CFU reduction) and IL-18 levels compared to bare VCM. These findings show the potential of NLC-VCM as a therapeutic platform that synergistically combines antibacterial action with host-directed immunomodulation to combat MRSA infections and sepsis.